Your session is about to expire
← Back to Search
Corticosteroid
Monotherapy TH-302 Dose Escalation for Multiple Myeloma
Phase 1 & 2
Waitlist Available
Research Sponsored by Threshold Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
Approved for 60 Other Conditions
No Placebo-Only Group
Summary
This phase 2 study is designed to evaluate the safety and tolerability activity of TH-302 and dexamethasone with or without bortezomib or pomalidomide in subjects with relapsed/refractory multiple myeloma.
Eligible Conditions
- Multiple Myeloma
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Awards & Highlights
Approved for 60 Other Conditions
This treatment demonstrated efficacy for 60 other conditions.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
4Treatment groups
Experimental Treatment
Group I: TH-302 and Dexamethasone Dose ExpansionExperimental Treatment1 Intervention
Group II: TH-302 Dose Escalation and Dexamethasone with PomalidomideExperimental Treatment1 Intervention
Group III: TH-302 Dose Escalation and Dexamethasone with BortezomibExperimental Treatment1 Intervention
Group IV: Monotherapy TH-302 Dose EscalationExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Evofosfamide
Not yet FDA approved
Find a Location
Who is running the clinical trial?
Threshold PharmaceuticalsLead Sponsor
32 Previous Clinical Trials
3,767 Total Patients Enrolled
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger